Neogen Corporation announced a voluntary nationwide recall of its Neogen®Vet HYCOAT® Hyaluronate Sodium Sterile Solution, a veterinary product used for topical wound care in dogs, cats, and horses, after microbial contamination was detected in certain 10 mL/50 mg vials and adverse events were reported in horses that received the product for off‑label intra‑articular injections.
The recall covers specific lot numbers identified by the company, including 2 mL/20 mg and 10 mL/50 mg vials. The contamination, which posed an infection risk, prompted the company to pull the product from the market and notify veterinarians at the distributor level. The adverse events in horses were linked to the off‑label use of the product for joint injections, a use not approved by the FDA.
Because the HYCOAT® product is manufactured by a third‑party supplier and represents a minor portion of Neogen’s Animal Safety segment, the financial impact of the recall is expected to be limited. The company has stated that the recall will not materially affect its overall revenue or earnings for the quarter.
Neogen’s second‑quarter 2026 results provide context for the recall. The company reported revenue of $224.69 million, down 2.8% year‑over‑year but above consensus estimates of $207.85 million, and adjusted earnings per share of $0.10, beating estimates of $0.06. CEO Mike Nassif highlighted “significant sequential improvement in core revenue growth and profitability” and emphasized the company’s focus on integrating Petrifilm and optimizing sample‑collection manufacturing. Neogen also raised its fiscal 2026 sales forecast to $845 million–$855 million, up from the prior guidance of $820 million–$840 million.
Market reaction to the recall was muted. The company’s stock fell 2.8% on the day of the announcement, but analysts noted that the decline came after a 43% surge over the past 20 days and a 117% rise over the past 120 days. Despite the recall, analysts maintained a “Hold” rating, citing the limited financial impact and the company’s strong earnings performance and guidance upgrade.
The recall is viewed as a contained operational issue rather than a systemic problem. Neogen’s ongoing strategic transformation, including the integration of Petrifilm and a focus on core animal‑safety products, positions the company to manage the recall without significant disruption to its broader business. The company’s recent earnings beat and guidance raise suggest confidence in its operational execution and resilience in the face of short‑term headwinds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.